Live Breaking News & Updates on Lecanemab Clarity|Page 4
Stay updated with breaking news from Lecanemab clarity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Europe may still await its first disease-modifying Alzheimer’s drug after the EMA postponed its decision on Leqembi (lecanemab, Biogen Inc./Eisai Co. Ltd) on March 22, but leading members of the World Dementia Council were in an optimistic mood when they convened in London four days later. ....
A breakthrough new drug to treat brain disease is always welcome news. Last summer, the performance of the drugs donanemab and lecanemab in clinical trials. ....
Biogen Inc.’s problematic trip with Aduhelm (aducanumab-avwa) for Alzheimer’s disease at last came to an end as the company, probably surprising few on Wall Street, said it’s quitting sales and development of the amyloid-beta directed antibody. The drug won accelerated approval by the U.S. FDA in July 2021. ....
Biogen announced it will discontinue marketing the Alzheimer’s drug Aduhelm. This ends the tortuous saga of a once-promising treatment for the memory-robbing disease. ....